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ABSTRACT: Introduction: The correlation between monofila-
ment testing, symptom surveys, and electrodiagnostic studies for
the diagnosis of axonal polyneuropathy has not been well stud-
ied. This investigation was done to assess the agreement
between these procedures in a non-random sample of volun-
teers. Methods: The procedures evaluated included electrodiag-
nostic tests of the sural nerve, monofilament testing of the great
toe, a symptom survey, and a body diagram. Kappa coefficients
and sensitivity and specificity, using nerve conduction as a ‘gold
standard,’ were used to determine the agreement between vari-
ous combinations of procedures. Results: Poor agreement
(kappa values 0.12–0.44) and sensitivity (sensitivity <30%)
were found for all combinations of symptoms and monofilament
results in comparison with sural peak latency and amplitude.
Conclusions: Overall, the results demonstrated a low discrimina-
tory power for the screening procedures for identifying persons
with impaired sural nerve function. The results highlight the need
for further development and evaluation of screening methods for
distal neuropathy in population-based studies.
Muscle Nerve 45: 653–658, 2012
Peripheral neuropathy in the lower extremity is
clinically important in the general population.
Polyneuropathy can have a variety of causes,
including exposure to toxins, metabolic disorders,
or infection. The detection of mild peripheral neu-
ropathy may require careful clinical examination
and/or the use of electrodiagnostic testing. The
American Academy of Neurology and others have
offered consensus deﬁnitions of polyneuropathy.1
Quick and accurate screening and clinical diagno-
ses rely on high sensitivity and speciﬁcity for the
methods employed. The sensitivity and speciﬁcity
of the techniques employed signiﬁcantly affect the
outcomes of clinical screening and are also impor-
tant for epidemiological research of peripheral
neuropathy in the lower extremity.
Several tools and procedures, such as electro-
diagnostic testing, quantitative sensory tests, physi-
cal examination procedures, body diagrams, and
symptom questionnaires, have been employed for
screening and epidemiological research of periph-
eral neuropathy. Each of these tools and proce-
dures has strengths and weaknesses. Both electro-
diagnostic testing and quantitative sensory tests are
highly reproducible and complementary to each
other.2–4 However, the role of quantitative sensory
tests in the diagnosis of distal neuropathy requires
further study.1 The advantage of electrodiagnostic
testing is that it provides an objective measure of
peripheral nerve function, which clinical psycho-
physical examinations do not offer. Therefore, to
detect peripheral neuropathy in the lower extrem-
ities, sural nerve conduction testing is considered
to be an appropriate tool.5 However, electrodiag-
nostic testing requires speciﬁc equipment and
training for examiners.
The objective of this study was to assess the
agreement between electrodiagnostic testing,
monoﬁlament testing, a lower extremity symptom
survey, and a body diagram in the identiﬁcation of
possible peripheral neuropathy in the feet. The
analysis for the assessment was carried out in a
population of dental professionals.
METHODS
Subjects were recruited during the Michigan Den-
tal Association (MDA) annual conventions held in
2009 (n ¼ 232) and 2010 (n ¼ 283). Participants
were comprised of a convenience sample of dental
professionals who attended the conventions and
were recruited for a gene–environment study that
investigated the relationship between nerve con-
duction tests and urinary and hair mercury bio-
markers. Each participant signed a written
informed consent document approved by the insti-
tutional review board of University of Michigan
(HUM00027621).
Electrodiagnostic Testing. Nerve conduction tests
performed included amplitude, onset latency, and
peak latency of the sural nerve in the right ankle.
We chose to only present results based on ampli-
tude and peak latency, and not onset latency. The
latter is highly correlated with peak latency, and
measurement of peak latency tends to have better
reliability than onset latency.4 A TECA Synergy de-
vice (Oxford Instruments, Hawthorne, New York)
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was used to record the amplitude and peak latency
after stimulation was applied to the posterior as-
pect of the right calf, 14 cm proximal to the stand-
ard recording electrode placed behind the lateral
malleolus in the lower extremity. The temperature
of the right midfoot was recorded at the time of
measurement. Feet were warmed with electric heat-
ing pads if the limb temperature was initially
<32C. The peak latency (milliseconds) was
deﬁned as the time required for an electrical stim-
ulus to reach peak deﬂection from baseline of an
action potential waveform. The amplitude (micro-
volts) was deﬁned as the baseline-to-peak voltage
difference of the waveform. We took the best
supramaximal stimulation of several trials for our
amplitude measurements. All parameters were
recorded in accordance with the guidelines out-
lined by the American Association of Electrodiag-
nostic Medicine.6
Self-Administrated Symptom Questionnaire and Body
Diagram. Each subject completed a self-adminis-
tered questionnaire to collect information on dem-
ographics and current symptoms of the lower
extremities along with pre-existing diseases. If sub-
jects reported any symptoms in their feet in the
week prior to the survey, they were asked to report
the duration of time they felt numbness and/or
tingling in their feet: at <6 weeks; at 6–12 weeks;
or at >12 weeks (Sx). Due to small numbers, the
duration of symptoms was excluded from subse-
quent analyses.
Subjects also completed a self-administrated
full-body symptom diagram. They were asked to
shade areas where numbness, tingling, burning, or
pain had occurred more than three times, or had
lasted >1 week in the previous 6 months. In this
analysis, only areas at or below the right ankle
were reviewed and scored independently by two
raters for symptoms consistent with neuropathy in
the feet. Any discrepancies were reconciled
between the two raters through consensus. The
results of body diagram symptoms (BDS) were clas-
siﬁed into three categories with respect to symp-
tom distribution consistent with neuropathy in the
feet, including probable, possible, and unlikely
(see Appendix for speciﬁc deﬁnitions). Symptoms
consistent with neuropathy in the feet were
deﬁned in different ways using combinations of
the body diagram and symptom questionnaire.
Monofilament Testing. The plantar surface of the
great toe on the right foot was tested for periph-
eral sensation using a 5.07-gauge Semmes–Wein-
stein nylon monoﬁlament (Wound Central, Au-
rora, Illinois).7 We chose one monoﬁlament
instead of all 20 monoﬁlaments in order to sim-
plify the data collection by minimizing the time
spent on each subject and maximizing the sample
size of the study. The 5.07-gauge monoﬁlament
has been shown to be the best predictor among all
20 monoﬁlaments to determine the loss of protec-
tive sensation in the feet among diabetic subjects.8
The use of a single monoﬁlament resulted in a sin-
gle outcome (‘‘positive’’ or ‘‘negative’’). Prior to
the test, patients were asked to feel the monoﬁla-
ment on their ﬁngertip. The monoﬁlament was
then applied up to three times to the right great
toe with sufﬁcient force to bend the ﬁlament.
Patients were asked to indicate when a touch
occurred. The test result was recorded as abnormal
if a subject did not indicate a monoﬁlament touch
on two consecutive attempts.
Statistical Analyses. Abnormal sural nerve func-
tion was deﬁned by two separate criteria used by
the University of Michigan Electroneuromyography
Laboratory: (1) age-adjusted peak latency >4.1 ms
(20–60 years old) or >5 ms (>60 years old); and
(2) age-adjusted amplitude 6 lV (20–60 years
old) or 5 lV (>60 years old). In addition to age
adjustment, the corrected peak latency was deﬁned
by adjusting to a standard temperature of 32C
based on the following formula: latencycorrected ¼
latencyinitial  0.3 ms  (32-T)C.9 No temperature
adjustment was applied to amplitudes, because, in
our data, temperature was not a predictor of the
sural amplitude in multivariate linear regression
analysis (not shown). Due to missing values (n ¼
56) for foot temperature, the sample size for peak
latency was smaller than that for amplitude.
Because nerve conduction and monoﬁlament
tests were conducted only on the right foot, the
analyses describe only those results for the right
foot. All analyses were performed using SAS soft-
ware, version 9.2 (SAS Institute, Inc., Cary, North
Carolina). Agreement of electrodiagnostic ﬁndings
with symptoms consistent with neuropathy in the
feet and monoﬁlament results, respectively, was
assessed by kappa coefﬁcients. Separate kappa
coefﬁcients were calculated for all subjects, dia-
betic subjects, and non-diabetic subjects. Kappa
results were interpreted as excellent (>0.75), fair
to good (0.40–0.75), or poor (<0.40).10 Pearson
chi-square tests or Fisher exact tests were per-
formed to assess the association of electrodiagnos-
tic ﬁndings with symptoms consistent with neurop-
athy in the feet and monoﬁlament results. Using
sural nerve function (peak latency and/or ampli-
tude) as the gold standard, sensitivity and speciﬁc-
ity of various combinations of the other tests (body
diagram, symptom questionnaire, and monoﬁla-
ment) were calculated. To reﬂect the clinical rele-
vance of the nerve function as continuous meas-
urements, we also calculated the mean nerve
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function stratiﬁed by various combinations of the
clinical tests just noted. Normality tests showed
that the distributions were not normal for temper-
ature- and age-adjusted peak latency (Shapiro–Wilk
¼ 0.98; P < 0.0001) and amplitude (Shapiro–Wilk
¼ 0.94; P < 0.0001). The mean amplitude and cor-
rected peak latency were compared between test
strata using non-parametric Mann–Whitney tests.
RESULTS
The prevalence of self-reported diabetes was
approximately 4% (Table 1). Diabetic subjects
were signiﬁcantly older and had higher body mass
index (BMI) than non-diabetic subjects. The pro-
portions of positive ﬁndings for the various symp-
tom criteria (Table 2) are shown in Table 3.
Except for peak latency, the proportions of posi-
tive ﬁndings in the diabetic subjects were higher
than those in the non-diabetic subjects. In general,
the proportion of abnormal nerve function ﬁnd-
ings was higher than that of abnormal monoﬁla-
ment results.
The main results are summarized in Table 4.
Overall, kappa values (0.12–0.44) were mostly
poor, sensitivity was low, and speciﬁcity was high.
Monoﬁlament testing appeared to perform slightly
better than symptom surveys among non-diabetic
subjects. Not surprisingly, results among diabetic
subjects were somewhat better than among non-di-
abetic subjects. However, the number of diabetic
subjects was small, so the conﬁdence intervals tend
to be broad, and none of the results achieved sta-
tistical signiﬁcance. Chi-square test statistics and P-
values showed that signiﬁcant associations in all
subjects occurred only in those combinations hav-
ing kappa values that were among the highest. In
Tables S1–S3 (see Supplementary Material), we
also showed kappa values, sensitivity, and speciﬁcity
for the combinations of monoﬁlament ﬁndings
and symptom results in comparison with abnormal
amplitude or peak latency, abnormal peak latency
alone, or abnormal amplitude alone, respectively.
We observed similar patterns in the low kappa
coefﬁcients, high sensitivity, and low speciﬁcity.
Table 1. Demographic characteristics of study subjects.
N Overall Diabetic (n ¼ 23) Non-diabetic (n ¼ 492) Men (n ¼ 197)
Age (years) 512 52.00 56.77* 51.79* 59.28
BMI (kg/m2) 26.41 29.15† 26.29† 26.91
*P < 0.05;
†P < 0.005.
Table 2. Neuropathy definitions from results of body diagram scores and symptom questionnaire.
Symptom consistent with neuropathy Abbreviation Definition
Definition a: Body diagram score BDS Probable or possible body diagram score for neuropathy
Definition b: Body diagram score and
numbness and/or tingling in feet
BDS and Sx Probable or possible body diagram score for
neuropathy and numbness and/or tingling in feet
Definition c: Body diagram score or
numbness and/or tingling in feet
BDS or Sx Probable or possible body diagram score for
neuropathy or numbness and/or tingling in feet
Table 3. Prevalence of subjects with positive findings among all subjects and for diabetic and non-diabetic subjects.
Total
subjects
Diabetic
subjects
Total
subjects
w/ findings Percent
Diabetic
subjects
w/ findings Percent
Non-diabetic
subjects
w/ findings Percent
Temperature and age-adjusted nerve conduction test
Peak latency >4.1 ms (or 5 ms) 453 19 85 18.76 3 15.79 82 18.89
Amplitude 6 lV (or 5 lV) 491 20 50 10.18 4 20.00 46 9.77
Peak latency >4.1 ms (or 5 ms) and
amplitude 6 lV (or 5 lV)
453 19 16 3.53 2 10.53 14 3.23
Peak latency >4.1 ms (or 5 ms) or
amplitude 6 lV (or 5 lV)
491 20 119 24.24 5 25.00 114 24.20
Symptom consistent with neuropathy in feet
BDS 515 23 35 6.80 4 17.39 31 6.30
BDS and Sx 515 23 27 5.24 3 13.04 24 4.88
BDS or Sx 515 23 75 14.56 10 43.48 65 13.21
Monofilament test 501 21 17 3.39 3 14.29 14 2.92
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Comparisons of means of nerve function
between screening test strata were performed using
Mann–Whitney tests (see Tables S4 and S5 in Sup-
plementary Material). Given the small numbers,
none of the means differed signiﬁcantly for either
sural amplitude or peak latency among diabetic
subjects. Results for all subjects and for non-dia-
betic subjects were similar. The means of peak la-
tency did not differ signiﬁcantly for any screening
outcome deﬁned purely on the basis of the body
diagram with or without symptoms. In contrast,
the comparison of mean amplitudes differed sig-
niﬁcantly in the expected direction for the body
diagram and for most combinations of the body
diagram with symptoms. The mean peak latency
among all subjects with a positive monoﬁlament
test (mean ¼ 4.13 ms) was signiﬁcantly greater
than among those with a negative monoﬁlament
test (mean ¼ 3.51 ms; P ¼ 0.05). Consistent with
the latency results, the mean amplitude among all
subjects with a positive monoﬁlament test (mean ¼
6.71 lV) was signiﬁcantly lower than among those
with a negative monoﬁlament test (mean ¼ 13.12
lV; P < 0.0001). Despite these differences, the
overlap of the distributions of nerve test results
when stratiﬁed by screening test outcome was con-
siderable (see Fig. S1 in Supplementary Material).
DISCUSSION
In this study we assessed the agreement between
electrodiagnostic testing results (sural nerve peak
latency and amplitude), monoﬁlament ﬁndings,
and symptoms consistent with neuropathy in the
right foot of a non-random convenience sample of
dental professionals. Overall, the low kappa coefﬁ-
cients showed poor agreement between electro-
diagnostic tests and the other procedures. Kappa
coefﬁcients in diabetic subjects were somewhat
higher than in non-diabetic subjects.
Using nerve conduction as the gold standard,
the sensitivity and speciﬁcity of various combina-
tions of the screening tests were mostly low and
high, respectively. The results of mean differences
in nerve function (see Tables S4 and S5 in Supple-
mentary Material) revealed some signiﬁcant differ-
ences, but the clinical utility of these differences
may be limited by the observed considerable over-
lap of the distributions of ‘‘normal’’ and ‘‘abnor-
mal’’ screening results. These ﬁndings highlight
the potential inﬂuence of nerve function cut-off
values and the potential importance of using nerve
function as a continuous versus dichotomous out-
come in comparing test procedures. Unlike other
clinical procedures that produce binary outcomes,
nerve conduction is measured on a continuum. Pe-
ripheral neuropathy, deﬁned by measured nerve
function, is therefore a continuum. This may have
had an impact on the results of poor agreement
between the screening procedures, although the
direction of such an impact was not clear. How-
ever, as shown in Figure S1 (Supplementary Mate-
rial), there was considerable overlap of the distri-
butions of nerve conduction parameters among
those with normal and abnormal screening test
results based on monoﬁlaments, body diagrams, or
symptoms.
In this study we examined the agreement
between different screening tools and procedures
for neuropathy in the lower extremity in a non-
random convenience sample of volunteers. A simi-
lar study that investigated such agreement in the
upper extremity also reported relatively poor
agreement between physical examinations, electro-
diagnostic ﬁndings, and symptoms consistent with
carpal tunnel syndrome.11 The current results
point to a need for further development and evalu-
ation of the methods used to screen for neuropa-
thy in the feet. The low prevalence of positive ﬁnd-
ings highlights the challenge in developing a
screening tool for peripheral neuropathy for use
in non-clinical populations, because positive pre-
dictive value and negative predictive value are a
function of prevalence, and not just sensitivity and
speciﬁcity. Overall, the results demonstrate a low
discriminatory power between the screening proce-
dures for identifying persons with impaired sural
nerve function in a non-random convenience sam-
ple of volunteers.
This study was supported by a NIOSH training grant (T42 OH
008455-04) from the University of Michigan Center for Occupa-
tional Health and Safety Engineering and a grant (UL1RR024986)
from the Michigan Institute for Clinical and Health Research.
Y.W. was supported by the Michigan Risk Science Center Summer
Fellowship and by funds from the Department of Environmental
Health Sciences, School of Public Health, University of Michigan.
J.G. was supported by a training grant (T32 007062) from the
NIEHS Environmental Toxicology and Epidemiology. This
research was approved by the institutional review board of the Uni-
versity of Michigan (HUM00027621).
REFERENCES
1. England JD, Gronseth GS, Franklin G, Miller RG, Asbury AK, Carter
GT, et al. Distal symmetric polyneuropathy: a deﬁnition for clinical
research: report of the American Academy of Neurology, the Ameri-
can Association of Electrodiagnostic Medicine, and the American
Academy of Physical Medicine and Rehabilitation. Neurology 2005;
64:199–207.
2. Kincaid J, Price K, Jimenez M, Skljarevski V. Correlation of vibratory
quantitative sensory testing and nerve conduction studies in patients
with diabetes. Muscle Nerve 2007;36:821–827.
3. Bird S, Brown M, Spino C, Watling S, Foyt H. Value of repeated
measures of nerve conduction and quantitative sensory testing in a
diabetic neuropathy trial. Muscle Nerve 2006;34:214–224.
4. Salerno DF, Werner RA, Albers JW, Becker MP, Armstrong TJ, Franz-
blau A. Reliability of nerve conduction studies among active workers.
Muscle Nerve 1999;22:1372.
5. Kimura J. Principles and pitfalls of nerve conduction studies. Ann
Neurol 1984;16:415.
6. American Association of Electrodiagnostic Medicine. Practice param-
eter for electrodiagnostic studies in carpal tunnel syndrome: sum-
mary statement. Muscle Nerve 2002;25:918.
Agreement of Neuropathy Screening Methods MUSCLE & NERVE May 2012 657
7. Herman W, Kennedy L. Underdiagnosis of peripheral neuropathy in
type 2 diabetes. Diabetes Care 2005;28:1480–1481.
8. Feng Y, Schlsser F, Sumpio B. The Semmes Weinstein monoﬁlament
examination as a screening tool for diabetic peripheral neuropathy.
J Vasc Surg 2009;50:675–682.
9. Tong H, Werner R, Franzblau A. Effect of aging on sensory nerve
conduction study parameters. Muscle Nerve 2004;29:716–720.
10. Streiner D, Norman G. Health measurement scales: a practical guide
to their development and use, 4th ed. London: Oxford University
Press; 1994.
11. Homan MM, Franzblau A, Werner RA, Albers JW, Armstrong TJ,
Bromberg MB. Agreement between symptom surveys, physical ex-
amination procedures and electrodiagnostic ﬁndings for the car-
pal tunnel syndrome. Scand J Work Environ Health 1999;25:
115–124.
APPENDIX
The criteria for defining neuropathy in the feet
are as follows:
2—Probable
• If both feet are entirely shaded.
• If a large portion of both feet, including all toes,
is shaded.
• If all toes are shaded in both feet.
1—Possible
• If shaded areas include one or more but not all
of the toes.
• If shaded areas include anywhere in the foot but
not toes.
• If shaded areas include anywhere in the foot
including toes.
• If one foot is fully shaded but the other foot has
only partial shading.
0—Unlikely
• If no shading anywhere on feet below ankle.
• If other non-lateral parts of foot are shaded; toes
are not shaded.
• If no shading anywhere on toes regardless of
shading elsewhere.
• If shading is present on only one foot.
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